Literature DB >> 20350286

Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals.

Christian Doutremepuich1, Omar Aguejouf, Vanessa Desplat, Francisco X Eizayaga.   

Abstract

UNLABELLED: Aspirin administration decreases the risk of vascular ischemic problems. However, aspirin withdrawal may temporarily increase this risk. Previous studies reported that high dilutions of aspirin might cause a pro-thrombotic effect. This paper studies the effect of the lower end of the aspirin dose-response curve, its possible mechanism and clinical implications. PROTOCOL: Wistar rats were distributed into 100 groups of 10 rats each. Aspirin was injected at 100 mg/kg, 1 mg/kg and at several different aspirin dilutions along with cyclooxygenase (COX) 1 (SC-560), COX 2 (NS-398) or both selective inhibitors simultaneously using a laser-induced thrombosis model.
RESULTS: The higher doses of aspirin decreased thrombosis. An opposite trend was observed with the lowest doses. SC-560 produced an anti-thrombotic effect antagonized by the highest aspirin dilutions. NS-398 created a pro-thrombotic effect that was antagonized by aspirin at higher doses. Simultaneous inhibition of COX 1 and 2 produced changes similar to COX 1 inhibition.
CONCLUSION: COX 2 inhibition induced a pro-thrombotic effect that was antagonized by aspirin at 1 mg/kg or 100 mg/kg. The administration of the lowest aspirin doses induced a pro-thrombotic effect stronger than the antithrombotic effect of COX 1 selective inhibition. The mechanism of this last pro-thrombotic effect is induced by residual aspirin and is independent of COX 1 inhibition. This study may explain the cause of the paradoxical thrombo-embolic complications observed after aspirin discontinuation, an effect of residual aspirin rather than a rebound effect, and highlights the importance of low doses of substances as a barely studied source of side-effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350286     DOI: 10.2174/187152910791292510

Source DB:  PubMed          Journal:  Cardiovasc Hematol Disord Drug Targets        ISSN: 1871-529X


  4 in total

1.  Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation.

Authors:  Jefferson C Frisbee; Adam G Goodwill; Phoebe A Stapleton; Stephanie J Frisbee; Alexandre C d'Audiffret
Journal:  Physiol Genomics       Date:  2010-06-08       Impact factor: 3.107

Review 2.  Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

3.  Cell-Specific Gene Deletion Reveals the Antithrombotic Function of COX1 and Explains the Vascular COX1/Prostacyclin Paradox.

Authors:  Jane A Mitchell; Fisnik Shala; Youssef Elghazouli; Timothy D Warner; Carles Gaston-Massuet; Marilena Crescente; Paul C Armstrong; Harvey R Herschman; Nicholas S Kirkby
Journal:  Circ Res       Date:  2019-09-12       Impact factor: 17.367

4.  Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation.

Authors:  Jane A Mitchell; Fisnik Shala; Maria Elisa Lopes Pires; Rachel Y Loy; Andrew Ravendren; Joshua Benson; Paula Urquhart; Anna Nicolaou; Harvey R Herschman; Nicholas S Kirkby
Journal:  Sci Adv       Date:  2021-03-19       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.